Advertisement

The Modulatory Effects of the Polymorphisms in GLA 5′-Untranslated Region Upon Gene Expression Are Cell-Type Specific

  • Susana FerreiraEmail author
  • Carlos Reguenga
  • João Paulo Oliveira
Research Report
Part of the JIMD Reports book series (JIMD, volume 23)

Abstract

Lysosomal α-galactosidase A (αGal) is the enzyme deficient in Fabry disease (FD). The 5′-untranslated region (5′UTR) of the αGal gene (GLA) shows a remarkable degree of variation with three common single nucleotide polymorphisms at nucleotide positions c.-30G>A, c.-12G>A and c.-10C>T. We have recently identified in young Portuguese stroke patients a fourth polymorphism, at c.-44C>T, co-segregating in cis with the c.-12A allele. In vivo, the c.-30A allele is associated with higher enzyme activity in plasma, whereas c.-10T is associated with moderately decreased enzyme activity in leucocytes. Limited data suggest that c.-44T might be associated with increased plasma αGal activity. We have used a luciferase reporter system to experimentally assess the relative modulatory effects on gene expression of the different GLA 5′UTR polymorphisms, as compared to the wild-type sequence, in four different human cell lines. Group-wise, the relative luciferase expression patterns of the various GLA variant isoforms differed significantly in all four cell lines, as evaluated by non-parametric statistics, and were cell-type specific. Some of the post hoc pairwise statistical comparisons were also significant, but the observed effects of the GLA 5′UTR polymorphisms upon the luciferase transcriptional activity in vitro did not consistently replicate the in vivo observations.

These data suggest that the GLA 5′UTR polymorphisms are possible modulators of the αGal expression. Further studies are needed to elucidate the biological and clinical implications of these observations, particularly to clarify the effect of these polymorphisms in individuals carrying GLA variants associated with high residual enzyme activity, with no or mild FD clinical phenotypes.

Keywords

Jurkat Cell Fabry Disease Residual Enzyme Activity Relative Luciferase Activity Portuguese Population 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

These studies have been partially supported by a donation from Sanofi-Genzyme (Portugal) for research in Fabry disease. However, Sanofi-Genzyme was not involved in any way either with the design or the development of this study, including the analyses of the experimental data, or with the decision to publish their results.

We thank Deolinda Lima, M.D., Ph.D., for providing the facilities of the Laboratory of Support to Research in Molecular Medicine (LAIMM), at the Department of Experimental Biology, of the Faculty of Medicine, University of Porto (FMUP), Portugal, where most of the experimental work was performed.

We thank Ana Moço, MSc Student, from the Biocomposites Group, Institute of Biomedical Engineering (INEB), Faculty of Engineering, University of Porto (FEUP), Portugal, for generously providing the HDMEC cells; José Pedro Castro, Ph.D. Student, from the Department of Experimental Biology, Centre for Medical Research, FMUP, for generously providing the Jurkat cells; and Ana Grangeia, Ph.D., from the Genetics Department, FMUP, for generously providing the HEK-293 cells.

Supplementary material

References

  1. Baptista MV, Ferreira S, Pinho EMT et al (2010) Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study–screening genetic conditions in Portuguese young stroke patients. Stroke 41:431–436PubMedCrossRefGoogle Scholar
  2. Barrett LW, Fletcher S, Wilton SD (2012) Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements. Cell Mol Life Sci 69:3613–3634PubMedCentralPubMedCrossRefGoogle Scholar
  3. Brady RO, Gal AE, Bradley RM, Martensson E (1967) The metabolism of ceramide trihexosides. I. Purification and properties of an enzyme that cleaves the terminal galactose molecule of galactosylgalactosylglucosylceramide. J Biol Chem 242:1021–1026PubMedGoogle Scholar
  4. Brogan J, Li F, Li W, He Z, Huang Q, Li CY (2012) Imaging molecular pathways: reporter genes. Rad Res 177:508–513CrossRefGoogle Scholar
  5. Davies JP, Winchester BG, Malcolm S (1993) Sequence variations in the first exon of alpha-galactosidase A. J Med Genet 30:658–663PubMedCentralPubMedCrossRefGoogle Scholar
  6. Desnick RJ, Ioannou YA, Eng CM (2001) α-Galactosidase A deficiency: Fabry disease In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds). The metabolic and molecular basis of inherited disease. McGraw-Hill, New York, pp. 3733–3774Google Scholar
  7. Ferreira S, Ortiz A, Germain DP et al (2015) The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: Data from individual patients and family studies. Mol Genet Metab 114(2):248–258.Google Scholar
  8. Ferri L, Guido C, la Marca G et al (2012) Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene. Clin Genet 81:224–233PubMedCrossRefGoogle Scholar
  9. Fitzmaurice TF, Desnick RJ, Bishop DF (1997) Human alpha-galactosidase A: high plasma activity expressed by the -30G→A allele. J Inherit Metab Dis 20:643–657PubMedCrossRefGoogle Scholar
  10. Garman SC (2007) Structure-function relationships in alpha-galactosidase A. Acta Paediatr (Suppl 96):6–16Google Scholar
  11. Germain DP (2010) Fabry disease. Orphanet J Rare Dis 5:30PubMedCentralPubMedCrossRefGoogle Scholar
  12. Jacobs JL, Dinman JD (2004) Systematic analysis of bicistronic reporter assay data. Nucleic Acids Res 32:e160PubMedCentralPubMedCrossRefGoogle Scholar
  13. Kint JA (1970) The enzyme defect in Fabry’s disease. Nature 227:1173PubMedCrossRefGoogle Scholar
  14. Macville M, Schrock E, Padilla-Nash H et al (1999) Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by spectral karyotyping. Cancer Res 59:141–150PubMedGoogle Scholar
  15. Niemann M, Rolfs A, Giese A et al (2013) Lyso-Gb3 indicates that the alpha-galactosidase A mutation D313Y is not clinically relevant for fabry disease. JIMD Rep 7:99–102PubMedCentralPubMedCrossRefGoogle Scholar
  16. Oliveira JP, Ferreira S, Barcelo J et al (2008a) Effect of single-nucleotide polymorphisms of the 5′ untranslated region of the human alpha-galactosidase gene on enzyme activity, and their frequencies in Portuguese caucasians. J Inherit Metab Dis 31(Suppl 2):S247–S253PubMedCrossRefGoogle Scholar
  17. Oliveira JP, Ferreira S, Reguenga C, Carvalho F, Mansson JE (2008b) The g.1170C>T polymorphism of the 5′ untranslated region of the human alpha-galactosidase gene is associated with decreased enzyme expression–evidence from a family study. J Inherit Metab Dis 31(Suppl 2):S405–S413Google Scholar
  18. Richard L, Velasco P, Detmar M (1999) Isolation and culture of microvascular endothelial cells. Methods Mol Med 18:261–269PubMedGoogle Scholar
  19. Saifudeen Z, Desnick RJ, Ehrlich M (1995) A mutation in the 5′ untranslated region of the human alpha-galactosidase A gene in high-activity variants inhibits specific protein binding. FEBS Lett 371:181–184PubMedCrossRefGoogle Scholar
  20. Samac S, Rice JC, Ehrlich M (1998) Analysis of methylation in the 5′ region of the human alpha-galactosidase A gene containing a binding site for methylated DNA-binding protein/RFX1-4. Biol Chem 379:541–544PubMedGoogle Scholar
  21. Schneider U, Schwenk HU, Bornkamm G (1977) Characterization of EBV-genome negative “null” and “T” cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer 19:621–626PubMedCrossRefGoogle Scholar
  22. Shaw G, Morse S, Ararat M, Graham FL (2002) Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. Faseb j 16:869–871PubMedGoogle Scholar
  23. von Scheidt W, Eng CM, Fitzmaurice TF et al (1991) An atypical variant of Fabry’s disease with manifestations confined to the myocardium. N Engl J Med 324:395–399CrossRefGoogle Scholar
  24. Warnock DG (2005) Fabry disease: diagnosis and management, with emphasis on the renal manifestations. Curr Opin Nephrol Hypertens 14:87–95PubMedCrossRefGoogle Scholar
  25. Wu G, Yan B, Wang X et al (2008) Decreased activities of lysosomal acid alpha-D-galactosidase A in the leukocytes of sporadic Parkinson's disease. J Neurol Sci 271:168–173PubMedCrossRefGoogle Scholar
  26. Wu G, Pang S, Feng X et al (2011) Genetic analysis of lysosomal alpha-galactosidase A gene in sporadic Parkinson’s disease. Neurosci Lett 500:31–35PubMedCrossRefGoogle Scholar
  27. Yasuda M, Shabbeer J, Benson SD, Maire I, Burnett RM, Desnick RJ (2003) Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele. Hum Mutat 22:486–492PubMedCrossRefGoogle Scholar
  28. Zhang XY, Asiedu CK, Supakar PC, Khan R, Ehrlich KC, Ehrlich M (1990) Binding sites in mammalian genes and viral gene regulatory regions recognized by methylated DNA-binding protein. Nucleic Acids Res 18:6253–6260PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© SSIEM and Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Susana Ferreira
    • 1
    Email author
  • Carlos Reguenga
    • 2
    • 3
  • João Paulo Oliveira
    • 1
    • 4
  1. 1.Department of Genetics, Faculty of MedicineUniversity of PortoPortoPortugal
  2. 2.Department of Experimental Biology, Faculty of MedicineUniversity of PortoPortoPortugal
  3. 3.Institute for Molecular and Cell BiologyPortoPortugal
  4. 4.Genetics Clinic, São João Hospital CentrePortoPortugal

Personalised recommendations